Our data showed that fingolimod could improve the disease course, alleviate the decrease in inflammation, and reduce proinflammatory cytokines through the Akt/mTOR/NF‐κB axis in c‐EAN rats, which could be beneficial for the development of CIDP‐related research. The gene discussed is NFKB1; the disease is chronic inflammatory demyelinating polyradiculoneuropathy.